Related Experiment Videos
Nebulized gentamicin in children and adolescents with cystic fibrosis
Insights
Nebulized gentamicin showed potential benefits for children with cystic fibrosis (CF) by reducing lung function decline in those with Pseudomonas aeruginosa. However, it did not significantly impact overall clinical symptoms or hospitalizations.
Area of Science:
- Pediatric Pulmonology
- Infectious Diseases
- Cystic Fibrosis Research
Background:
- Cystic fibrosis (CF) is a genetic disorder affecting lung function.
- Pseudomonas aeruginosa infection is a common complication in CF patients.
- Inhaled antibiotics are used to manage chronic infections in CF.
Purpose of the Study:
- To evaluate the efficacy of nebulized gentamicin in children and adolescents with CF.
- To assess the impact of gentamicin on clinical symptoms, pulmonary function, and P. aeruginosa colonization.
- To compare gentamicin inhalation with a saline control over a 2-year period.
Main Methods:
- A 2-year study involving 29 children and adolescents with CF.
- Participants received either nebulized gentamicin (20 mg twice daily) or a nebulized saline mixture.
- Outcomes measured included clinical symptoms, lung function, antibiotic use, hospital days, and P. aeruginosa development.
Main Results:
- No significant differences were observed in antibiotic usage, hospital days, or clinical symptoms between groups.
- Subjects with P. aeruginosa in sputum showed significantly less deterioration in lung function with gentamicin.
- No differences in progress were noted for subjects already colonized with P. aeruginosa at baseline.
Conclusions:
- Nebulized gentamicin may help preserve lung function in CF patients with P. aeruginosa.
- Gentamicin did not demonstrate significant benefits for overall clinical status or infection rates in this cohort.
- Further research is warranted to optimize inhaled antibiotic strategies for CF patients.
Abstract:
A study of 29 children and adolescents with cystic fibrosis over 2 years showed some evidence of benefit from the twice daily inhalation of 20 mg nebulized gentamicin when compared to the inhalation of a nebulized saline mixture. Clinical symptoms, deterioration in pulmonary function, antibiotic usage, days in hospital and development of Pseudomonas aeruginosa in the sputum were recorded. There was no significant difference in antibiotic usage, days in hospital or clinical symptoms between the two regimes. Those subjects with P. aeruginosa in sputum showed significantly less deterioration in lung function over 2 years while using gentamicin aerosol. There was no difference in progress between the two treatment regimes for those subjects with P. aeruginosa in sputum at the beginning of the study, nor was there any difference in the number developing P. aeruginosa in sputum.